SI1173205T1 - Oralna formulacija za dajanje v ileum, ki obsega inhibitorsko spojino transporta žolčne kisline v ileumu - Google Patents

Oralna formulacija za dajanje v ileum, ki obsega inhibitorsko spojino transporta žolčne kisline v ileumu

Info

Publication number
SI1173205T1
SI1173205T1 SI200030695T SI200030695T SI1173205T1 SI 1173205 T1 SI1173205 T1 SI 1173205T1 SI 200030695 T SI200030695 T SI 200030695T SI 200030695 T SI200030695 T SI 200030695T SI 1173205 T1 SI1173205 T1 SI 1173205T1
Authority
SI
Slovenia
Prior art keywords
inhibitor compound
bile acid
ileum
administering
acid transport
Prior art date
Application number
SI200030695T
Other languages
English (en)
Inventor
Bertil Abrahamsson
Ann-Margret Lindqvist
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1173205T1 publication Critical patent/SI1173205T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
SI200030695T 1999-04-19 2000-04-19 Oralna formulacija za dajanje v ileum, ki obsega inhibitorsko spojino transporta žolčne kisline v ileumu SI1173205T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations
EP00928046A EP1173205B1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
PCT/SE2000/000755 WO2000062810A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport

Publications (1)

Publication Number Publication Date
SI1173205T1 true SI1173205T1 (sl) 2005-10-31

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030695T SI1173205T1 (sl) 1999-04-19 2000-04-19 Oralna formulacija za dajanje v ileum, ki obsega inhibitorsko spojino transporta žolčne kisline v ileumu

Country Status (27)

Country Link
EP (1) EP1173205B1 (sl)
JP (1) JP2002542208A (sl)
KR (1) KR20010108516A (sl)
CN (1) CN1348384A (sl)
AT (1) ATE296641T1 (sl)
AU (1) AU767425B2 (sl)
BR (1) BR0009835A (sl)
CA (1) CA2379105A1 (sl)
CZ (1) CZ20013743A3 (sl)
DE (1) DE60020551T2 (sl)
DK (1) DK1173205T3 (sl)
EE (1) EE04607B1 (sl)
ES (1) ES2241603T3 (sl)
HK (1) HK1042850A1 (sl)
HU (1) HUP0200793A3 (sl)
IL (1) IL145871A0 (sl)
IS (1) IS2161B (sl)
NO (1) NO20015063D0 (sl)
NZ (1) NZ514264A (sl)
PL (1) PL351186A1 (sl)
PT (1) PT1173205E (sl)
SE (1) SE9901387D0 (sl)
SI (1) SI1173205T1 (sl)
SK (1) SK15282001A3 (sl)
TR (1) TR200103033T2 (sl)
WO (1) WO2000062810A1 (sl)
ZA (1) ZA200108539B (sl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
HU229291B1 (en) * 2001-01-31 2013-10-28 Evonik Roehm Gmbh Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
EP1427423B9 (en) 2001-09-08 2017-12-20 AstraZeneca AB Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
WO2009140599A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
CN102316889B (zh) 2008-11-26 2014-11-26 萨蒂奥根制药公司 组合物及使用方法
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
RS56231B1 (sr) 2010-02-04 2017-11-30 Morphotek Inc Polipeptidi i konjugati hlorotoksina i njihove upotrebe
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ES2586931T3 (es) 2010-11-08 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
RU2619215C2 (ru) * 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
US20150316536A1 (en) 2012-12-10 2015-11-05 Fred Hutchinson Cancer Research Center Methods for screening
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601745B (zh) 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP7448490B2 (ja) 2018-06-20 2024-03-12 アルビレオ・アクチボラグ オデビキシバットの医薬製剤
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
MX2021009625A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Métodos para incrementar el crecimiento en sujetos pediátricos que tienen enfermedad de hígado colestásico.
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
FI4069360T3 (fi) 2019-12-04 2024-02-20 Albireo Ab Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
TW289020B (sl) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
EE200100545A (et) 2003-02-17
CA2379105A1 (en) 2000-10-26
EP1173205A1 (en) 2002-01-23
WO2000062810A1 (en) 2000-10-26
DE60020551D1 (de) 2005-07-07
ES2241603T3 (es) 2005-11-01
BR0009835A (pt) 2002-01-08
AU767425B2 (en) 2003-11-13
NO20015063L (no) 2001-10-18
NZ514264A (en) 2003-10-31
IS2161B (is) 2006-11-15
SK15282001A3 (sk) 2002-04-04
HK1042850A1 (en) 2002-08-30
DK1173205T3 (da) 2005-08-08
JP2002542208A (ja) 2002-12-10
TR200103033T2 (tr) 2002-03-21
EP1173205B1 (en) 2005-06-01
KR20010108516A (ko) 2001-12-07
IL145871A0 (en) 2002-07-25
SE9901387D0 (sv) 1999-04-19
PT1173205E (pt) 2005-10-31
NO20015063D0 (no) 2001-10-18
CN1348384A (zh) 2002-05-08
PL351186A1 (en) 2003-03-24
HUP0200793A2 (hu) 2002-07-29
CZ20013743A3 (cs) 2002-01-16
IS6109A (is) 2001-10-16
ZA200108539B (en) 2003-01-17
AU4633500A (en) 2000-11-02
ATE296641T1 (de) 2005-06-15
DE60020551T2 (de) 2006-03-23
EE04607B1 (et) 2006-04-17
HUP0200793A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
HK1042850A1 (en) An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport.
SE0003766D0 (sv) Novel formulation
NZ514574A (en) Novel method of treatment
BG66114B1 (bg) Многофазов състав на дросперидон като контрацептив
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
IL134778A0 (en) Pharmaceutical compositions for oral administration of molecular iodine
GEP20022784B (en) Celecoxib Composition
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
MY118156A (en) Oral compositions of levosimendan.
EP1007055A4 (en) METHODS OF ADMINISTERING AMIFOSTINE
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
TW198685B (sl)
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
JP2002500181A5 (sl)
CA2408920A1 (en) Methods for prevention of ulcers and improving physiological performance
AU2002236587A1 (en) Compositions for adhesion prevention
BG104692A (en) Extended release tiagabine formulation
AU2003241629A1 (en) An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
CA2329665A1 (en) Treatment of depression and pharmaceutical preparations therefor
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
MY132962A (en) Inotropic agents with negative chronotropic and vasodilatory effects
AU1580395A (en) Microgranules of 5-nitro imidazole derivatives
UA36576A (uk) Спосіб корекції реактивності організму у хворих на інфаркт міокарда в гострому та підгострому періодах
MX9804819A (es) Antagonistas de hormona liberadora de gonadotropina.